Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 272

1.

Rebuttal from dr veatch.

Veatch RM.

Chest. 2015 Jun;147(6):1458-9. doi: 10.1378/chest.15-0276. No abstract available.

PMID:
26033125
2.
3.

Killing by organ procurement: brain-based death and legal fictions.

Veatch RM.

J Med Philos. 2015 Jun;40(3):289-311. doi: 10.1093/jmp/jhv007. Epub 2015 Apr 18.

PMID:
25889264
4.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

PMID:
25758770
5.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.

PMID:
25519451
6.

Revisiting multi-organ transplantation in the setting of scarcity.

Reese PP, Veatch RM, Abt PL, Amaral S.

Am J Transplant. 2014 Jan;14(1):21-6. doi: 10.1111/ajt.12557.

7.

Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial.

Woodruff PG, Chatila W, Connett JE, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Marchetti N, Rogers TJ, Scanlon PD, Sin DD, Voelker H, Wendt C, Albert RK; COPD Clinical Research Network.

Eur Respir J. 2014 Jan;43(1):295-8. doi: 10.1183/09031936.00140613. Epub 2013 Oct 17. No abstract available.

8.

Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes.

Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV; Diabetes Research in Children Network (DirecNet) Study Group; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2013 Dec;36(12):4030-5. doi: 10.2337/dc13-1074. Epub 2013 Oct 15.

9.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17.

10.

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1.

11.

The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis.

Diabetes Research in Children Network (DirecNet) Study Group; Type 1 Diabetes TrialNet Study Group, Buckingham BA, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Cantwell M.

Diabetes Technol Ther. 2013 May;15(5):401-8. doi: 10.1089/dia.2013.0002. Epub 2013 Apr 9.

12.

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T; AIDA Study Group.

Lancet. 2013 Jun 1;381(9881):1905-15. doi: 10.1016/S0140-6736(13)60023-9. Epub 2013 Apr 5.

13.

Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.

Kroll JL, Beam C, Li S, Viscidi R, Dighero B, Cho A, Boulware D, Pescovitz M, Weinberg A; Type 1 Diabetes TrialNet Anti CD-20 Study Group.

J Clin Virol. 2013 Jun;57(2):115-9. doi: 10.1016/j.jcv.2013.01.016. Epub 2013 Feb 17.

14.

Repeating an attending physician's unseemly remarks.

Ubel PA, Veatch RM.

Virtual Mentor. 2012 Sep 1;14(9):688-94. doi: 10.1001/virtualmentor.2012.14.9.ecas1-1209. No abstract available.

15.

Equal Opportunity Supplemented by Fair Innings: equity and efficiency in allocating deceased donor kidneys.

Ross LF, Parker W, Veatch RM, Gentry SE, Thistlethwaite JR Jr.

Am J Transplant. 2012 Aug;12(8):2115-24. doi: 10.1111/j.1600-6143.2012.04141.x. Epub 2012 Jun 15.

16.

Authority figures.

Veatch RM.

Hastings Cent Rep. 2012 May-Jun;42(3):4-5 author reply 6-7. doi: 10.1002/hast.42. No abstract available.

PMID:
22627714
17.

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies.

Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2012 Jun;35(6):1213-8. doi: 10.2337/dc11-2081. Epub 2012 Mar 23.

18.

Influence of lightweight ambulatory oxygen on oxygen use and activity patterns of COPD patients receiving long-term oxygen therapy.

Casaburi R, Porszasz J, Hecht A, Tiep B, Albert RK, Anthonisen NR, Bailey WC, Connett JE, Cooper JA Jr, Criner GJ, Curtis J, Dransfield M, Lazarus SC, Make B, Martinez FJ, McEvoy C, Niewoehner DE, Reilly JJ, Scanlon P, Scharf SM, Sciurba FC, Woodruff P; COPD Clinical Research Network.

COPD. 2012 Feb;9(1):3-11. doi: 10.3109/15412555.2011.630048.

PMID:
22292592
19.

Hippocratic, religious, and secular ethics: the points of conflict.

Veatch RM.

Theor Med Bioeth. 2012 Feb;33(1):33-43. doi: 10.1007/s11017-011-9203-z.

PMID:
22237805
20.

Effect of rituximab on human in vivo antibody immune responses.

Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A; Type 1 Diabetes TrialNet Study Group.

J Allergy Clin Immunol. 2011 Dec;128(6):1295-1302.e5. doi: 10.1016/j.jaci.2011.08.008. Epub 2011 Sep 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk